Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reissue Patent
2006-09-05
2006-09-05
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S278000
Reissue Patent
active
RE039267
ABSTRACT:
Various thienopyrimidine-based analog compounds that selectively inhibit the Src family of tyrosine kinases. These compounds are thienopyrimidines and contain a hydrozone bridge created by heating a thienopyrimidine hydrazine with an aldehyde in ethanol at reflux. Such compounds are useful in the treatment of various diseases including hyperproliferative diseases, hematologic diseases, osteoporosis, neurological diseases, autoimmune diseases, allergic/immunological diseases, or viral infections.
REFERENCES:
patent: 4146716 (1979-03-01), Cox et al.
patent: 4196207 (1980-04-01), Webber
patent: 4562193 (1985-12-01), Yamamoto et al.
patent: 4845097 (1989-07-01), Matsumoto et al.
patent: 5593997 (1997-01-01), Dow et al.
patent: 5639757 (1997-06-01), Dow et al.
patent: 5668140 (1997-09-01), Schaper et al.
patent: 5948911 (1999-09-01), Pamukcu et al.
patent: 6096749 (2000-08-01), Traxler et al.
patent: 6096750 (2000-08-01), Gangjee
patent: 1057612 (1967-02-01), None
patent: 0 356 158 (1990-02-01), None
patent: 0356158 (1990-02-01), None
patent: 0447891 (1991-09-01), None
patent: 0 447 891 (1991-09-01), None
patent: 0452002 (1991-10-01), None
patent: 0 452 002 (1991-10-01), None
patent: 1116486 (2001-07-01), None
patent: 2042061 (1980-10-01), None
patent: 2 042 067 (1980-10-01), None
patent: WO 88/08842 (1988-11-01), None
patent: WO 95/19774 (1995-07-01), None
patent: WO 96/14319 (1996-05-01), None
patent: WO 97/09878 (1997-03-01), None
patent: WO 97/13771 (1997-04-01), None
patent: WO-97/29110 (1997-08-01), None
patent: WO 97/29110 (1997-08-01), None
patent: WO 99/24440 (1999-05-01), None
patent: WO 00/16766 (2000-03-01), None
patent: WO 01/04102 (2001-01-01), None
patent: WO 01/66099 (2001-09-01), None
Tatosyan et al., Review: Kianse of the Src family: Structure and Functions, Institute of Cracinogenesis, Blokhin Cancer Research Center, Russian Academy of Medical Science.
Database Crossfire Beilstein, Robba et al., j. Heterocyclic Chem., 12:525, 527, 1985, XP-002211314.
Database CA, Robba et al., J. Heterocycl. Chem., 12:252-527, 1975, XP-002211315.
Database CA, Robba et al., C. R. Acad. Sci., 266:128-130, 1968, XP-002211316.
Database CA, Dave et al., Heterocycles, 51:1819-1826, 1999, XP-002211317.
Easmon et al., “Azinyl and Diazinyl Hydrazones derived from Aryl N-Heteroaryl Ketones: Synthesis and Antiproliferative Activity,”Journal of Medicinal Chemistry, American Chemical Society,40:4420-4425, 1997.
Hozien et al., “Synthesis and Application of Some New Thienopyrimidine Derivatives as Antimicrobial Agents,”Synthetic Communications,20:3733-3755, 1996.
Sawutz et al., “In Vitro Characterization of a Novel Series of Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors”,Biochemical Pharmacology,51:1631-1638, 1996.
Barnekow, “Functional aspects of the c-src gene,”Crit. Rev. Oncogen.,1:277-292, 1989.
Bolen and Brugge, “Leukocyte protein tyrosine kinases: potential targets for drug discovery,”Annu Rev Immunol,15:371-404, 1997.
Bolen et al., “Analysis of pp60c-src in human colon carcinoma and normal human colon mucosal cells,”Oncogene Res,1:149-168, 1987.
Bolen et al., “Increased pp60c-src tyrosyl kinase activity in human neuroblastomas is associated with amino-terminal tyrosine phosphorylation of the src gene product,”Proc Natl Acad Sci82:7275-7279, 1985.
Briggs, et al., “Affinity of Src Family Kinase SH3 Domains for HIV Nef in Vitro Does Not Predict Kinase Activation by Nef in Vivo,”Biochemistry,39(3):489-495, 2000.
Burke, Jr. et al., “Bicyclic compounds as ring constrained inhibitors of protein-tyrosine kinase p561ck,”J. Med. Chem,36:425-432, 1993.
Burke, Jr., “Protein-tyrosine kinase inhibitors,”Drugs of the Future17:119-131, 1992.
Burke, Jr., “Protein-tyrosine kinases: potential targets for anticancer drug design,”Stem Cells,12:1-6, 1994.
Cartwright et al., “Activation of the pp60c-src protein kinase is an early event in colonic carcinogenesis,”Proc Natl Acad Sci USA,87:558-562, 1990.
Chackalaparampil and Shalloway, “Altered phosphorylation and activation of pp60c-src during fibroblast mitosis,”Cell,52:801-810, 1988.
Chang and Geahlen, “Protein-tyrosine kinase inhibition: mechanism-based discovery of anti-tumor agents,”J. Nat. Prod.,55:1529-1560, 1992.
Chen et al., “Structure-activity relationships in a series of 5-[(2,5-dihydroxybenzyl) amino]salicylate inhibitors of EGF-receptor-associated tyrosine kinase: importance of additional hydrophobic aromatic interactions,”J. Med. Chem.,37:845-859, 1994.
Choi, et al., “Role of Hck in the Pathogenesis of Encephalomyocarditis Virus-Induced Diabetes in Mice,”Journal of Virology,75(4):1949-1957, 2001.
Collette and Olive, “Non-receptor protein tyrosine kinases as immune targets of viruses,”Immunology Today,18:393-400. 1997.
Corey and Anderson, “Src-Related Protein Tyrosine Kinases in Hematopoiesis,”Blood,93:1-14, 1999.
Cushman et al., “Synthesis and evaluation of new protein-tyrosine kinase inhibitors. Part 1. Pyridine-containing stilbenes and amides,”Biorg. Med. Chem. Lett.,1:211-214, 1991.
Cushman et al., “Synthesis and evaluation of new protein-tyrosine kinase inhibitors. Part 2. Phenylhyrazones,”Biorg. Med. Chem. Lett.,1:215-218, 1991.
Cushman et al., “Synthesis and protein-tyrosine kinase inhibitory activities of flavonoid analogues,”J. Med. Chem.,34:798-806, 1991.
Dave et al., “Gould-Jacob type of reaction in the synthesis of thieno[3,2-e]pyrimido[1,2-c] pyrimidines: a comparison of classical heating vs solvent-free microwave irridation,”Heterocycles,51:1819-1826, 1999.
Dow et al., “Identification of tricyclic analogs related to ellagic acid as potent/selective tyrosine kinase inhibitors,”J. Med. Chem.,37:2224-2231, 1994.
Dunant and Ballmer-Hofer, “Signaling by Src Family Kinases: Lessons Learnt from DNA Tumour Viruses,”Cell. Signal.,9:385-393, 1997.
Ellis et al., “Down-regulation of Vascular Endothelial Growth Factor in a Human Colon Carcinoma Cell Line Transfected with an Antisense Expression Vector Specific for c-src,”J. Biol. Chem.,273:1052-1057, 1998.
Felsenfeld, et al., “Selective regulation of integrin-cytoskeleton interactions by the tyrosine kinase Src,”Nature Cell Biology,1:200-205, 1999.
Fry et al., “A specific inhibitor of the epidermal growth factor receptor tyrosine kinase,”Science,265:1093-1095, 1994.
Garcia et al., “Effect of herbimycin A on growth and pp60c-srcactivity in human colon tumor cell lines,”Oncogene,6:1983-1991, 1991.
Hall et al., “Evidence that c-src is involved in the process of osteoclastic bone resorption,”Biochem. Biophys. Res. Commun.,199:1237-1244, 1994.
Hibbs and Dunn, “Lyn, a src-like tyrosine kinase,”Int J Biochem Cell Biol,29:397-400, 1997.
Jessup and Gallick, “The biology of colorectal carcinoma,”Curr Problems in Cancer,16:263-328, 1992.
Katada et al., “Cytotoxic effects of NSL-1406, a new thienopyrimidine derivative, on leukocytes and osteoclasts,”Bioorg. Medic. Chem. Lett.,9:797-802, 1999.
Kitanaka et al., “Antisense src expression inhibits proliferation and erythropoietin-induced erythroid differentiation of K562 human leukemia cells,”Biochem Biophysic Res Commun,201:1534-1540, 1994.
Klein and Schneider, “Activation of Src Family Kinases by Hepatitis B Virus HBx Protein and Coupled Signaling to Ras,”Mol Cell Biol,17:6427-6436, 1997.
Lee et al., “Tau interacts with src-family non-receptor tyrosine kinases,”Journal of Cell Science,111:3167-3177, 1998.
Luttrell et al., “Involvement of pp60c-src with two major signaling pathways in human breast cancer,”Proc Natl Acad Sci,91:83-87, 1994.
Maquire et al., “A new series of PDGF receptor tyrosine kinase inhibitors: 3-substituted quinoline de
Benish Michele A.
Budde Raymond J. A.
Lawless Michael
Berch Mark L.
Board of Regents , The University of Texas System
Fulbright & Jaworski L.L.P.
Habte Kahsay
LandOfFree
Thienopyrimidine-based inhibitors of the SRC family does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thienopyrimidine-based inhibitors of the SRC family, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thienopyrimidine-based inhibitors of the SRC family will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3618776